Attached files
| file | filename |
|---|---|
| 10-K/A - 10-K/A - PRECIGEN, INC. | d144806d10ka.htm |
| EX-32.3 - EX-32.3 - PRECIGEN, INC. | d144806dex323.htm |
| EX-32.4 - EX-32.4 - PRECIGEN, INC. | d144806dex324.htm |
| EX-99.1 - EX-99.1 - PRECIGEN, INC. | d144806dex991.htm |
| EX-31.4 - EX-31.4 - PRECIGEN, INC. | d144806dex314.htm |
| EX-31.3 - EX-31.3 - PRECIGEN, INC. | d144806dex313.htm |
Exhibit 23.2
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in Registration Statements Nos. 333-190614, 333-196840 and 333-205642 on Form S-8 and No. 333-198598 on Form S-3 of Intrexon Corporation of our report dated February 24, 2016, relating to our audits of the financial statements of ZIOPHARM Oncology, Inc. which appears in the Annual Report on Form 10-K/A of Intrexon Corporation for the year ended December 31, 2015.
| /s/ RSM US LLP |
| Boston, Massachusetts |
| March 11, 2016 |